Clinical Trial Update: Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome [Phase 2]

View source ↗

Summary

Open-label extension study assessing the safety of efgartigimod in adults with primary Sjögren's syndrome; the study completed and results were posted in Februa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• Efgartigimod (efgartigimod)

Snippet

Sponsor: argenx | Conditions: Primary Sjögren's Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2026-02-20